These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27525312)

  • 41. Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.
    Nozaki Y; Fujita K; Wada K; Yoneda M; Kessoku T; Shinohara Y; Imajo K; Ogawa Y; Nakamuta M; Saito S; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
    BMC Gastroenterol; 2015 Apr; 15():42. PubMed ID: 25881230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Endogenous cannabinoid system regulates intestinal barrier function in vivo through cannabinoid type 1 receptor activation.
    Zoppi S; Madrigal JL; Pérez-Nievas BG; Marín-Jiménez I; Caso JR; Alou L; García-Bueno B; Colón A; Manzanares J; Gómez-Lus ML; Menchén L; Leza JC
    Am J Physiol Gastrointest Liver Physiol; 2012 Mar; 302(5):G565-71. PubMed ID: 22135307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endothelial nitric oxide synthase is not essential for the development of fibrosis and portal hypertension in bile duct ligated mice.
    Koshy A; De Gottardi A; Ledermann M; Saegesser H; Shaw SG; Zimmermann A; Reichen J
    Liver Int; 2005 Oct; 25(5):1044-52. PubMed ID: 16162165
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure.
    Zhang P; Xu X; Hu X; van Deel ED; Zhu G; Chen Y
    Circ Res; 2007 Apr; 100(7):1089-98. PubMed ID: 17363700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endocannabinoids regulate adipokine production and the immune balance of omental adipose tissue in human obesity.
    Ge Q; Maury E; Rycken L; Gérard J; Noël L; Detry R; Navez B; Brichard SM
    Int J Obes (Lond); 2013 Jun; 37(6):874-80. PubMed ID: 22868830
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis.
    Ishimura N; Bronk SF; Gores GJ
    Gastroenterology; 2005 May; 128(5):1354-68. PubMed ID: 15887117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway.
    Grouix B; Sarra-Bournet F; Leduc M; Simard JC; Hince K; Geerts L; Blais A; Gervais L; Laverdure A; Felton A; Richard J; Ouboudinar J; Gagnon W; Leblond FA; Laurin P; Gagnon L
    J Pharmacol Exp Ther; 2018 Oct; 367(1):71-81. PubMed ID: 30093459
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antifibrotic role of inducible nitric oxide synthase.
    Ferrini MG; Vernet D; Magee TR; Shahed A; Qian A; Rajfer J; Gonzalez-Cadavid NF
    Nitric Oxide; 2002 May; 6(3):283-94. PubMed ID: 12009846
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New strategy for the antifibrotic therapy with oral administration of FR260330 (a selective inducible nitric oxide synthase inhibitor) in rat experimental liver cirrhosis.
    Kikuchi H; Katsuramaki T; Kukita K; Taketani S; Meguro M; Nagayama M; Isobe M; Mizuguchi T; Hirata K
    Wound Repair Regen; 2007; 15(6):881-8. PubMed ID: 18028137
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modulation of inducible nitric oxide synthase pathway by eugenol and telmisartan in carbon tetrachloride-induced liver injury in rats.
    Fathy M; Khalifa EMMA; Fawzy MA
    Life Sci; 2019 Jan; 216():207-214. PubMed ID: 30452970
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of Inducible Nitric Oxide Synthase Attenuates Deficits in Synaptic Plasticity and Brain Functions Following Traumatic Brain Injury.
    Wang B; Han S
    Cerebellum; 2018 Aug; 17(4):477-484. PubMed ID: 29556966
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction of nitric oxide synthase and over-production of nitric oxide by interleukin-1beta in cultured lacrimal gland acinar cells.
    Beauregard C; Brandt PC; Chiou GC
    Exp Eye Res; 2003 Jul; 77(1):109-14. PubMed ID: 12823994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
    Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
    Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Suppression of lipopolysaccharide-induced nitric oxide synthase expression by platelet-activating factor receptor antagonists in the rat liver and cultured rat Kupffer cells.
    Mustafa SB; Flickinger BD; Olson MS
    Hepatology; 1999 Nov; 30(5):1206-14. PubMed ID: 10534342
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Temporal expression of hepatic inducible nitric oxide synthase in liver cirrhosis.
    Wei CL; Hon WM; Lee KH; Khoo HE
    World J Gastroenterol; 2005 Jan; 11(3):362-7. PubMed ID: 15637745
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Li L; Serriere-Lanneau V; Ledent C; Mallat A; Lotersztajn S
    Nat Med; 2006 Jun; 12(6):671-6. PubMed ID: 16715087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The protective action of ketanserin against lipopolysaccharide-induced shock in mice is mediated by inhibiting inducible NO synthase expression via the MEK/ERK pathway.
    Liu C; Zhang X; Zhou JX; Wei W; Liu DH; Ke P; Zhang GF; Cai GJ; Su DF
    Free Radic Biol Med; 2013 Dec; 65():658-666. PubMed ID: 23954471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists.
    Janero DR
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):17-29. PubMed ID: 22335400
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potent antioxidant role of pirfenidone in experimental cirrhosis.
    Salazar-Montes A; Ruiz-Corro L; López-Reyes A; Castrejón-Gómez E; Armendáriz-Borunda J
    Eur J Pharmacol; 2008 Oct; 595(1-3):69-77. PubMed ID: 18652820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.
    Janero DR; Lindsley L; Vemuri VK; Makriyannis A
    Expert Opin Drug Discov; 2011 Oct; 6(10):995-1025. PubMed ID: 22646861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.